Literature DB >> 14610276

Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice.

M W Sleeman1, K Garcia, R Liu, J D Murray, L Malinova, M Moncrieffe, G D Yancopoulos, S J Wiegand.   

Abstract

Obesity plays a central role in the development of insulin resistance and type 2 diabetes. We therefore examined the effects of a modified form of ciliary neurotrophic factor [Axokine, which is hereafter referred to as ciliary neurotrophic factor (CNTF)Ax15], which uses a leptin-like mechanism to reduce body weight, in the db/db murine model of type 2 diabetes. In previous studies, weight loss produced by CNTF treatment could largely be attributed to its effects on food intake. In contrast, CNTFAx15 treatment of db/db mice caused significantly greater weight loss and marked improvements in diabetic parameters (e.g., levels of glucose, insulin, triglyceride, cholesterol, and nonesterified free fatty acids) than could be accounted for by reduced caloric intake alone. These beneficial effects, above and beyond those seen in animals controlled for either food restriction or body weight, correlated with the ability of CNTFAx15 to increase metabolic rate and energy expenditure and reduce hepatic steatosis while enhancing hepatic responsiveness to insulin. The hepatic effects were linked to rapid alterations in hepatic gene expression, most notably reduced expression of stearoyl-CoA desaturase 1, a rate-limiting enzyme in the synthesis of complex lipids that is also markedly suppressed by leptin in ob/ob mice. These observations further link the mechanisms of CNTF and leptin action, and they suggest important, beneficial effects for CNTF in diabetes that may be distinct from its ability to decrease food intake; instead, these effects may be more related to its influence on energy expenditure and hepatic gene expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610276      PMCID: PMC283586          DOI: 10.1073/pnas.2335926100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity.

Authors:  P D Lambert; K D Anderson; M W Sleeman; V Wong; J Tan; A Hijarunguru; T L Corcoran; J D Murray; K E Thabet; G D Yancopoulos; S J Wiegand
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

2.  Neuropeptide Y counteracts the anorectic and weight reducing effects of ciliary neurotropic factor.

Authors:  S Pu; H Dhillon; L L Moldawer; P S Kalra; S P Kalra
Journal:  J Neuroendocrinol       Date:  2000-09       Impact factor: 3.627

Review 3.  The ciliary neurotrophic factor and its receptor, CNTFR alpha.

Authors:  M W Sleeman; K D Anderson; P D Lambert; G D Yancopoulos; S J Wiegand
Journal:  Pharm Acta Helv       Date:  2000-03

4.  Unlike leptin, ciliary neurotrophic factor does not reverse the starvation-induced changes of serum corticosterone and hypothalamic neuropeptide levels but induces expression of hypothalamic inhibitors of leptin signaling.

Authors:  M Ziotopoulou; D M Erani; S M Hileman; C Bjørbaek; C S Mantzoros
Journal:  Diabetes       Date:  2000-11       Impact factor: 9.461

5.  Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice.

Authors:  J Shao; H Yamashita; L Qiao; J E Friedman
Journal:  J Endocrinol       Date:  2000-10       Impact factor: 4.286

6.  Leptin differentially regulates NPY and POMC neurons projecting to the lateral hypothalamic area.

Authors:  C F Elias; C Aschkenasi; C Lee; J Kelly; R S Ahima; C Bjorbaek; J S Flier; C B Saper; J K Elmquist
Journal:  Neuron       Date:  1999-08       Impact factor: 17.173

7.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Authors:  J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

8.  Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.

Authors:  Stephen Colagiuri; Carole A Cull; Rury R Holman
Journal:  Diabetes Care       Date:  2002-08       Impact factor: 19.112

9.  LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor.

Authors:  S Davis; T H Aldrich; N Stahl; L Pan; T Taga; T Kishimoto; N Y Ip; G D Yancopoulos
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

10.  Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss.

Authors:  Paul Cohen; Makoto Miyazaki; Nicholas D Socci; Aaron Hagge-Greenberg; Wolfgang Liedtke; Alexander A Soukas; Ratnendra Sharma; Lisa C Hudgins; James M Ntambi; Jeffrey M Friedman
Journal:  Science       Date:  2002-07-12       Impact factor: 47.728

View more
  32 in total

1.  Extending the reach of Exendin-4: new pathways in the control of body weight and glucose homeostasis.

Authors:  Deborah J Good
Journal:  Endocrinology       Date:  2012-05       Impact factor: 4.736

2.  Absence of ghrelin protects against early-onset obesity.

Authors:  Katherine E Wortley; Juan-Pablo del Rincon; Jane D Murray; Karen Garcia; Keiji Iida; Michael O Thorner; Mark W Sleeman
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Activation of astrocytes by CNTF induces metabolic plasticity and increases resistance to metabolic insults.

Authors:  Carole Escartin; Karin Pierre; Angélique Colin; Emmanuel Brouillet; Thierry Delzescaux; Martine Guillermier; Marc Dhenain; Nicole Déglon; Philippe Hantraye; Luc Pellerin; Gilles Bonvento
Journal:  J Neurosci       Date:  2007-07-04       Impact factor: 6.167

4.  Continued administration of ciliary neurotrophic factor protects mice from inflammatory pathology in experimental autoimmune encephalomyelitis.

Authors:  Tanja Kuhlmann; Leah Remington; Isabelle Cognet; Lyne Bourbonniere; Simone Zehntner; Florence Guilhot; Alexandra Herman; Angélique Guay-Giroux; Jack P Antel; Trevor Owens; Jean-François Gauchat
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

5.  Oleanolic acid derivative DKS26 exerts antidiabetic and hepatoprotective effects in diabetic mice and promotes glucagon-like peptide-1 secretion and expression in intestinal cells.

Authors:  Fei-Fei Chen; Jian-Ta Wang; Li-Xia Zhang; Shu-Fang Xing; Yun-Xia Wang; Kai Wang; Shu-Li Deng; Ji-Quan Zhang; Lei Tang; Hao-Shu Wu
Journal:  Br J Pharmacol       Date:  2017-07-26       Impact factor: 8.739

6.  Ciliary neurotrophic factor (CNTF) protects non-obese Swiss mice against type 2 diabetes by increasing beta cell mass and reducing insulin clearance.

Authors:  L F Rezende; G J Santos; J C Santos-Silva; E M Carneiro; A C Boschero
Journal:  Diabetologia       Date:  2012-02-19       Impact factor: 10.122

7.  Ciliary neurotrophic factor protects mice against streptozotocin-induced type 1 diabetes through SOCS3: the role of STAT1/STAT3 ratio in β-cell death.

Authors:  Luiz F Rezende; Gustavo J Santos; Everardo M Carneiro; Antonio C Boschero
Journal:  J Biol Chem       Date:  2012-10-04       Impact factor: 5.157

8.  Oncostatin m is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes.

Authors:  David Sanchez-Infantes; Ursula A White; Carrie M Elks; Ron F Morrison; Jeffrey M Gimble; Robert V Considine; Anthony W Ferrante; Eric Ravussin; Jacqueline M Stephens
Journal:  J Clin Endocrinol Metab       Date:  2013-12-02       Impact factor: 5.958

9.  Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference.

Authors:  Katherine E Wortley; Keith D Anderson; Karen Garcia; Jane D Murray; Lubomira Malinova; Rong Liu; Marshena Moncrieffe; Karen Thabet; Hilary J Cox; George D Yancopoulos; Stanley J Wiegand; Mark W Sleeman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

Review 10.  CNTF: a target therapeutic for obesity-related metabolic disease?

Authors:  Vance B Matthews; Mark A Febbraio
Journal:  J Mol Med (Berl)       Date:  2008-01-22       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.